The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of female pattern hair loss (FPHL).This 6-month, double-blind, placebo-controlled, 2:1 randomized clinical trial investigates whether daily supplementation with Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.
Female subjects with female pattern hair loss
45-65 years
Signed informed consent
The study participant is in good general condition for her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study.
Known or documented intolerance/allergy to any of the ingredients of the study product
Chronic wounds, erosions, pre-existing infected skin or inflammation in the study area
Suspected non-compliance
Late onset acne
Parallel
Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, amino acids, and other bioactive compounds, formulated to support hair growth and scalp health in women.
Dietary supplementDrinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
Placebo control
Other interventionDrinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
Increase in hair density
From phototrichogram on the Sagittal midline area of the scalp.
Change in hair shedding
Hair shedding will be assessed by collecting shed hairs during a standardized washing and combing procedure.
Click on the lead sponsor to view all of their trials.
